Editas Medicine Inc
NASDAQ:EDIT
Editas Medicine Inc
Free Cash Flow
Editas Medicine Inc
Free Cash Flow Peer Comparison
Competitive Free Cash Flow Analysis
Latest Figures & CAGR of Competitors
Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Editas Medicine Inc
NASDAQ:EDIT
|
Free Cash Flow
$-136.9m
|
CAGR 3-Years
10%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Free Cash Flow
$22.1B
|
CAGR 3-Years
10%
|
CAGR 5-Years
12%
|
CAGR 10-Years
14%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Free Cash Flow
$7.4B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
10%
|
|
Amgen Inc
NASDAQ:AMGN
|
Free Cash Flow
$7.4B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
3%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Free Cash Flow
$3.3B
|
CAGR 3-Years
3%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Free Cash Flow
$3.7B
|
CAGR 3-Years
22%
|
CAGR 5-Years
15%
|
CAGR 10-Years
24%
|
See Also
What is Editas Medicine Inc's Free Cash Flow?
Free Cash Flow
-136.9m
USD
Based on the financial report for Dec 31, 2023, Editas Medicine Inc's Free Cash Flow amounts to -136.9m USD.
What is Editas Medicine Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
-22%
Over the last year, the Free Cash Flow growth was 25%. The average annual Free Cash Flow growth rates for Editas Medicine Inc have been 10% over the past three years , -22% over the past five years .